Studies of ovarian cancer (OV) have also found that FJD may increase the sensitivity of OV to cisplatin by mediating the phosphoinositide 3-kinase (PI3K)/AKT or NF-κB pathways [7]. This evidence concerns the gene NFKB1 and ovarian carcinoma.